JNCE Jounce Therapeutics Inc

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in transforming the treatment pf cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients.

$8.14  +0.22 (2.78%)
As of 05/07/2021 15:59:45 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/27/2017
Outstanding shares:  51,208,357
Average volume:  287,640
Market cap:   $405,570,187
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    481116101
ISIN:        US4811161011
Sedol:      BDRW1N9
Valuation   (See tab for details)
PE ratio:   46.70
PB ratio:   1.49
PS ratio:   6.35
Return on equity:   -15.72%
Net income %:   -68.78%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy